Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Debt Repayment

Cash used to repay borrowings during the period.

Inventiva S.A.NASDAQ: IVA

Debt Repayment · Q4 FY2025 · quarter ended Dec 2025

Debt repayment turns negative

Q4 FY2025 debt repayment was -€1.58M, compared with €19.92M a year earlier.

Context

  • Debt repayment amounted to 133.4% of revenue in FY2025, down 83.2 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€1.58M— QoQ
Last fiscal yearDec 2025
-€5.98M-130.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-107.9%——
1 year-130.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

EUR · from the cash flow

Latest · FY2025
(5.98M) EUR
Year-over-year change
-130.0%

Debt Repayment vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -130.0% is the lowest of 4, against a peer median of +100.0%.
  • Debt repayment amounts to 133.4% of revenue for IVA, versus a peer median of 0.0%.
IVA Competitors
Debt Repayment for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$32.34M USD+164.9%—46.7%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$17.91M USD+19.4%+71.5%54.7%
IVAInventiva S.A.FY2025€5.98M EUR-130.0%—133.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD+100.0%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD———
RNACCartesian Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
IVVDInvivyd, Inc.LTM Mar 2026$0 USD——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding IVA) —+100.0%+71.5%0.0%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.